|4May 16, 8:31 AM ET

Poradosu Enrique 4

4 · Nuvectis Pharma, Inc. · Filed May 16, 2022

Insider Transaction Report

Form 4
Period: 2022-05-12
Poradosu Enrique
Chief Science & Business Off
Transactions
  • Purchase

    Common Stock

    2022-05-12$14.76/sh+370$5,4611,258,019 total
  • Purchase

    Common Stock

    2022-05-12$16.04/sh+300$4,8121,258,319 total
Footnotes (3)
  • [F1]Reflects the weighted average purchase price. The range of prices for the shares purchased was $14.60 to $15.05. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
  • [F2]Includes 48,399 shares of restricted stock and 60,000 restricted stock units.
  • [F3]Reflects the weighted average purchase price. The range of prices for the shares purchased was $15.99 to $16.08. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

Documents

1 file
  • 4
    tm2215423-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT